KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nektar Therapeutics (NKTR) Income from Continuing Operations (2016 - 2025)

Nektar Therapeutics (NKTR) has 16 years of Income from Continuing Operations data on record, last reported at 34988000.0 in Q3 2025.

  • For Q3 2025, Income from Continuing Operations rose 5.58% year-over-year to 34988000.0; the TTM value through Sep 2025 reached 113365000.0, up 32.19%, while the annual FY2024 figure was 118971000.0, 56.73% up from the prior year.
  • Income from Continuing Operations reached 34988000.0 in Q3 2025 per NKTR's latest filing, up from 39207000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 7251000.0 in Q4 2024 and bottomed at 159068000.0 in Q2 2022.
  • Average Income from Continuing Operations over 5 years is 74454578.95, with a median of 52363000.0 recorded in 2024.
  • Peak YoY movement for Income from Continuing Operations: tumbled 56.9% in 2021, then skyrocketed 117.7% in 2024.
  • A 5-year view of Income from Continuing Operations shows it stood at 146805000.0 in 2021, then surged by 54.63% to 66605000.0 in 2022, then soared by 38.5% to 40961000.0 in 2023, then soared by 117.7% to 7251000.0 in 2024, then plummeted by 582.53% to 34988000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Income from Continuing Operations were 34988000.0 in Q3 2025, 39207000.0 in Q2 2025, and 46421000.0 in Q1 2025.